ArticlePloS one2010
Blood peptidome-degradome profile of breast cancer.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Analysis of serum peptidome profiles of non-metastatic and metastatic feline mammary carcinoma using liquid chromatography-tandem mass spectrometry.BMC veterinary research · 2024Article
- Differential Serum Peptidomics Reveal Multi-Marker Models That Predict Breast Cancer Progression.Cancers · 2024Article
- Clinical ApoA-IV amyloid is associated with fibrillogenic signal sequence.The Journal of pathology · 2021Article
- Proteomics and its applications in breast cancer.American journal of cancer research · 2021Review
- Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.Breast cancer research : BCR · 2020Observational
- The liver matrisome - looking beyond collagens.JHEP reports : innovation in hepatology · 2020Review
- Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.Immunogenetics · 2019Review
- Characterization of the Ovarian Tumor Peptidome.Vitamins and hormones · 2018Article
- Novel Bioinformatics-Based Approach for Proteomic Biomarkers Prediction of Calpain-2 &Caspase-3 Protease Fragmentation: Application to βII-Spectrin Protein.Scientific reports · 2017Article
- Intact Cell MALDI-TOF MS on Sperm: A Molecular Test For Male Fertility Diagnosis.Molecular & cellular proteomics : MCP · 2016Article
- Prediction of Toxin Genes from Chinese Yellow Catfish Based on Transcriptomic and Proteomic Sequencing.International journal of molecular sciences · 2016Article
- The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.The Journal of biological chemistry · 2016Article
- Article
- Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.Journal of cancer research and clinical oncology · 2015Article
- Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes.Journal of proteome research · 2015Article
- Mechanistic peptidomics: factors that dictate specificity in the formation of endogenous peptides in human milk.Molecular & cellular proteomics : MCP · 2014Article
- Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.International journal of cancer · 2014Article
- Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer.Clinical chemistry · 2014Article
- The lymph self-antigen repertoire.Frontiers in immunology · 2013Review
- Quantitation of endogenous peptides using mass spectrometry based methods.Current opinion in chemical biology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCancer invasion and metastasis are closely associated with activities within the degradome; however, little is known about whether these activities can be detected in the blood of cancer patients. METHODOLOGY AND PRINCIPAL
findingsThe peptidome-degradome profiles of pooled blood plasma sampled from 15 breast cancer patients (BCP) and age, race, and menopausal status matched control healthy persons (HP) were globally characterized using advanced comprehensive separations combined with tandem Fourier transform mass spectrometry and new data analysis approaches that facilitated top-down peptidomic analysis. The BCP pool displayed 71 degradome protein substrates that encompassed 839 distinct peptidome peptides. In contrast, the HP 50 degradome substrates found encompassed 425 peptides. We find that the ratios of the peptidome peptide relative abundances can vary as much as >4000 fold between BCP and HP. The experimental results also show differential degradation of substrates in the BCP sample in their functional domains, including the proteolytic and inhibitory sites of the plasmin-antiplasmin and thrombin-antithrombin systems, the main chains of the extracellular matrix protection proteins, the excessive degradation of innate immune system key convertases and membrane attack complex components, as well as several other cancer suppressor proteins.
conclusionsDegradomics-peptidomics profiling of blood plasma is highly sensitive to changes not evidenced by conventional bottom-up proteomics and potentially provides unique signatures of possible diagnostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.